Compare Adaptive Biotechnologies Corp (ADPT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Merck & Co., Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Merck & Co., Inc. trades at $126.01 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 95.6× Adaptive Biotechnologies Corp's market cap, and Merck & Co., Inc. pays a 2.64% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MRK | |
|---|---|---|
Market Cap | $3.33B | $318.26B |
Sector | Health | Health |
52-Week High | $22.37 | $129.52 |
52-Week Low | $10.24 | $77.60 |
Enterprise Value | $3.19B | $361.68B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Merck (MRK) trades at $126.00, down 0.62% today, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported solid earnings beats in recent quarters, with Q1 2026 loss narrower than expected. Revenue reached $65.01B in 2025, with net income margin improving to 28.07%. Recent acquisition of Terns Pharmaceuticals for approximately $6.7 billion aims to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook remains positive with a consensus price target of $139.33, implying 11% upside, supported by 67.6% analyst buy ratings. Risks include rising debt-to-asset ratio to 36.06% in 2025 and projected net cash flow decline to -$3.3B in 2026. Competitive pressures in pharma and macroeconomic uncertainties could challenge growth, but strong profitability and dividend yield offer defensive appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
